Department of Laboratory Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki City, Nagasaki 852-8501, Japan.
Crit Care. 2010;14(4):R159. doi: 10.1186/cc9234. Epub 2010 Aug 24.
Sepsis is a serious medical condition that requires rapidly administered, appropriate antibiotic treatment. Conventional methods take three or more days for final pathogen identification and antimicrobial susceptibility testing. We organized a prospective observational multicenter study in three study sites to evaluate the diagnostic accuracy and potential clinical utility of the SeptiFast system, a multiplex pathogen detection system used in the clinical setting to support early diagnosis of bloodstream infections.
A total of 212 patients, suspected of having systemic inflammatory response syndrome (SIRS) caused by bacterial or fungal infection, were enrolled in the study. From these patients, 407 blood samples were taken and blood culture analysis was performed to identify pathogens. Whole blood was also collected for DNA Detection Kit analysis immediately after its collection for blood culture. The results of the DNA Detection Kit, blood culture and other culture tests were compared. The chosen antimicrobial treatment in patients whose samples tested positive in the DNA Detection Kit and/or blood culture analysis was examined to evaluate the effect of concomitant antibiotic exposure on the results of these analyses.
SeptiFast analysis gave a positive result for 55 samples, while 43 samples were positive in blood culture analysis. The DNA Detection Kit identified a pathogen in 11.3% (45/400) of the samples, compared to 8.0% (32/400) by blood culture analysis. Twenty-three pathogens were detected by SeptiFast only; conversely, this system missed five episodes of clinically significant bacteremia (Methicillin-resistant Staphylococcus aureus (MRSA), 2; Pseudomonas aeruginosa, 1; Klebsiella spp, 1; Enterococcus faecium, 1). The number of samples that tested positive was significantly increased by combining the result of the blood culture analysis with those of the DNA Detection Kit analysis (P = 0.01). Among antibiotic pre-treated patients (prevalence, 72%), SeptiFast analysis detected more bacteria/fungi, and was less influenced by antibiotic exposure, compared with blood culture analysis (P = 0.02).
This rapid multiplex pathogen detection system complemented traditional culture-based methods and offered some added diagnostic value for the timely detection of causative pathogens, particularly in antibiotic pre-treated patients. Adequately designed intervention studies are needed to prove its clinical effectiveness in improving appropriate antibiotic selection and patient outcomes.
败血症是一种严重的医学病症,需要迅速给予适当的抗生素治疗。传统方法需要三到四天才能最终确定病原体并进行药敏试验。我们在三个研究地点组织了一项前瞻性观察性多中心研究,以评估 SeptiFast 系统的诊断准确性和潜在临床应用价值。SeptiFast 系统是一种在临床环境中用于支持血流感染早期诊断的多重病原体检测系统。
共纳入 212 例疑似细菌或真菌感染引起的全身炎症反应综合征(SIRS)患者。从这些患者中采集了 407 份血样进行血培养分析以确定病原体。采集全血后立即进行 DNA 检测试剂盒分析,用于血液培养。比较 DNA 检测试剂盒、血培养和其他培养试验的结果。对 DNA 检测试剂盒和/或血培养分析阳性的患者选择的抗菌治疗进行检查,以评估同时使用抗生素对这些分析结果的影响。
SeptiFast 分析有 55 份样本呈阳性,而血培养分析有 43 份样本呈阳性。DNA 检测试剂盒在 11.3%(45/400)的样本中鉴定出病原体,而血培养分析为 8.0%(32/400)。SeptiFast 仅检测到 23 种病原体;相反,该系统漏诊了 5 例临床意义重大的菌血症(耐甲氧西林金黄色葡萄球菌(MRSA),2 例;铜绿假单胞菌,1 例;肺炎克雷伯菌,1 例;屎肠球菌,1 例)。将血培养分析结果与 DNA 检测试剂盒分析结果相结合,样本呈阳性的数量显著增加(P = 0.01)。在抗生素预处理患者中(患病率为 72%),与血培养分析相比,SeptiFast 分析检测到更多的细菌/真菌,且受抗生素暴露的影响较小(P = 0.02)。
这种快速的多重病原体检测系统补充了传统的基于培养的方法,并为及时检测病原体提供了一些附加的诊断价值,特别是在抗生素预处理患者中。需要进行充分设计的干预研究来证明其在改善抗生素选择和患者结局方面的临床效果。